Novo Nordisk A/S - Share repurchase programme
On 29 January 2009 Novo Nordisk initiated its share repurchase
programme in accordance with the provisions of the European
Commission's regulation no 2273/2003 of 22 December 2003, also
referred to as the Safe Harbour rules.
Under the programme Novo Nordisk will repurchase B shares for an
amount up to DKK 3.0 billion in the period from 29 January 2009 to 5
August 2009.
Since the announcement as of 30 March 2009, the following
transactions have been made under the programme:
Number of Average Transaction
shares purchase price value, DKK
Accumulated, last
announcement 3,317,500 944,916,745
30 March 2009 75,000 278.10 20,857,500
31 March 2009 150,000 272.99 40,948,650
1 April 2009 60,000 277.50 16,650,000
2 April 2009 70,000 276.54 19,357,800
3 April 2009 159,541 246.10 39,263,040
Accumulated under
the programme 3,832,041 1,081,993,735
Transactions related to Novo Nordisk's incentive programmes have
resulted in a net sale by Novo Nordisk of 170 B shares in the period
from 30 March 2009 to 3 April 2009. The shares in these transactions
were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of
28,684,423 treasury shares, corresponding to 4.5% of the share
capital. The total amount of shares in the company is 634,000,000
including treasury shares.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. In addition, Novo Nordisk has a leading position within areas
such as haemostasis management, growth hormone therapy and hormone
replacement therapy. Novo Nordisk manufactures and markets
pharmaceutical products and services that make a significant
difference to patients, the medical profession and society. With
headquarters in Denmark, Novo Nordisk employs more than 27,000
employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk's B shares are listed on the stock exchanges in
Copenhagen and London. Its ADRs are listed on the New York Stock
Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Kasper Roseeuw Poulsen
Tel: 4442 4471
krop@novonordisk.com
In North America: In North America:
Sean Clements Hans Rommer
Tel: (+1) 609 514 8316 Tel: (+1) 609 919 7937
secl@novonordisk.com hrmm@novonordisk.com
Company Announcement no 21 / 2009
